

Table S2. Demographics and disease characteristics prior to first-line therapy; patients with psoriatic arthritis initiating new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>	<u>All</u>
Patients Initiating First-Line Therapy	41	20	33	25	119
Age (years), N	41	20	33	25	119
Mean \pm SD	53.2 \pm 13.17	55.5 \pm 13.00	48.9 \pm 9.40	48.2 \pm 12.31	51.4 \pm 12.19
Gender, N	41	20	33	25	119
Male	22 (53.7)	15 (75.0)	17 (51.5)	15 (60.0)	69 (58.0)
Race, N	41	20	33	25	119
White	40 (97.6)	20 (100.0)	29 (87.9)	22 (88.0)	111 (93.3)
BMI (kg/m ²), N	41	20	32	25	118
Mean \pm SD	32.4 \pm 6.75	30.5 \pm 5.34	31.1 \pm 7.51	30.6 \pm 9.27	31.3 \pm 7.31
Years since psoriasis diagnosis, N ^a	41	19	32	25	117
Mean \pm SD	20.4 \pm 13.63	23.2 \pm 13.53	14.9 \pm 12.10	17.0 \pm 13.66	18.6 \pm 13.38
Percent BSA, N	41	20	33	24	118
Mean \pm SD	26.8 \pm 24.46	30.3 \pm 27.66	21.7 \pm 22.58	20.7 \pm 15.55	24.7 \pm 22.98
PGA Score, N	41	18	32	24	115
Mean \pm SD	3.0 \pm 1.26	2.7 \pm 1.18	2.6 \pm 1.05	2.6 \pm 0.83	2.7 \pm 1.11
PGA 4/5	15 (36.6)	4 (22.2)	4 (12.5)	2 (8.3)	25 (21.8)
Prior Therapy, N ^a	41	20	33	25	119
Phototherapy	24 (58.5)	14 (70.0)	18 (54.5)	11 (44.0)	67 (56.3)
Immunomodulators	21 (51.2)	11 (55.0)	21 (63.6)	13 (52.0)	66 (55.5)
Methotrexate	19 (46.3)	8 (40.0)	17 (51.5)	9 (36.0)	53 (44.5)
Cyclosporine	7 (17.1)	4 (20.0)	8 (24.2)	5 (20.0)	24 (20.2)

Data are presented as number of patients (%), unless otherwise indicated.

BMI=body mass index, BSA= body surface area, PGA=Physician's Global Assessment, SD=standard deviation.

^aDuration of psoriasis and prior therapies were collected at entry into the registry.